

# Proteomics and pancreatic cystic neoplasms: a pilot study

<b>Submission date</b> 03/06/2010	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 10/06/2010	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 10/06/2010	<b>Condition category</b> Digestive System	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

**Plain English summary of protocol**  
Not provided at time of registration

**Study website**  
<http://www.unige.ch>

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Prof Jean Louis Frossard

**Contact details**  
Service of Gastroenterology  
Dept of Internal Medicine  
Rue Micheli du Crest  
Geneva  
Switzerland  
1211

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**  
001

# Study information

## Scientific Title

Use of proteomics to differentiate between benign and potentially malignant pancreatic cystic neoplasms: a pilot study

## Study objectives

We postulate that a proteomic analysis of pancreatic cystic fluid from patients having a pancreatic cystic neoplasms would be more performant than any other technique to discriminate between benign and malignant lesions.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Ethic Committee of Hirslanden Clinic (Surgery Section), Bern approved in March 2009

## Study design

Prospective cohort proteomic analysis study

## Primary study design

Observational

## Secondary study design

Cohort study

## Study setting(s)

Hospital

## Study type(s)

Diagnostic

## Participant information sheet

Not available in web format, please use contact details below to request a patient information sheet

## Health condition(s) or problem(s) studied

Pancreatic disease

## Interventions

Prospective collection of pancreatic cystic fluid in patients undergoing open pancreatic surgery aimed at removing the cystic neoplasms. Cystic fluid samples collected by direct puncture and submitted to proteomic analysis.

## Intervention Type

Other

## Phase

Not Applicable

**Primary outcome measure**

To help find specific protein markers to better differentiate between benign and potentially malignant pancreatic cystic neoplasms

**Secondary outcome measures**

To correlate results of the proteomic analysis to pancreatic histologic staining of surgical samples

**Overall study start date**

01/06/2009

**Completion date**

31/12/2010

## Eligibility

**Key inclusion criteria**

1. Patients with pancreatic cystic neoplasms as demonstrated by CT scan planned for open surgery
2. Each patient gave his/her informed consent before surgery

**Participant type(s)**

Patient

**Age group**

Adult

**Sex**

Both

**Target number of participants**

10

**Key exclusion criteria**

1. Age < 18 years old
2. Pregnant women

**Date of first enrolment**

01/06/2009

**Date of final enrolment**

31/12/2010

## Locations

**Countries of recruitment**

Switzerland

**Study participating centre**  
**Service of Gastroenterology**  
Geneva  
Switzerland  
1211

## **Sponsor information**

**Organisation**  
Geneva University Hospital (Switzerland)

**Sponsor details**  
Rue Micheli Du Crest  
Genève  
Switzerland  
1211  
+41 (0)22 3729346  
jean-louis.frossard@hcuge.ch

**Sponsor type**  
Hospital/treatment centre

**Website**  
<http://www.hepatogastro.ch>

**ROR**  
<https://ror.org/01m1pv723>

## **Funder(s)**

**Funder type**  
Hospital/treatment centre

**Funder Name**  
Geneva University Hospital (Switzerland)

## **Results and Publications**

**Publication and dissemination plan**  
Not provided at time of registration

**Intention to publish date**

## **Individual participant data (IPD) sharing plan**

### **IPD sharing plan summary**

Not provided at time of registration